Page last updated: 2024-11-06

saterinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Saterinone is a synthetic, orally bioavailable, small-molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH). DHODH is a key enzyme in the de novo pyrimidine biosynthesis pathway, which is essential for the proliferation of cells. Saterinone has shown anti-proliferative activity in vitro and in vivo against a variety of cancer cell lines, including those resistant to standard chemotherapies. Saterinone has also been shown to have anti-inflammatory and immunomodulatory effects. It is currently under investigation in clinical trials for the treatment of cancer and other diseases. Saterinone's importance lies in its ability to inhibit the growth of cancer cells by blocking the production of pyrimidines, which are essential for DNA and RNA synthesis. It is also being studied for its potential therapeutic benefits in autoimmune diseases, as it can suppress the immune response.'
```

saterinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65874
CHEMBL ID2030222
SCHEMBL ID563554
MeSH IDM0163284

Synonyms (19)

Synonym
saterinone
bdf-8634
5-[4-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]-6-methyl-2-oxo-1h-pyridine-3-carbonitrile
unii-w4p85fo7gs
(+-)-1,2-dihydro-5-(p-(2-hydroxy-3-(4-(o-methoxyphenyl)-1-piperazinyl)propoxy)phenyl)-6-methyl-2-oxonicotinonitrile
102669-89-6
saterinone [inn]
saterinona
w4p85fo7gs ,
saterinonum
saterinona [spanish]
saterinonum [latin]
CHEMBL2030222
SCHEMBL563554
KLEKLDFUYOZELG-UHFFFAOYSA-N
1-[4-(3-cyano-1,2-dihydro-6-methyl-2-oxo-pyridin-5-yl)-penoxy]-3-[4-(2-methoxyphenyl)-piperazin-1-yl]-propan-2-ol
DTXSID30883106
5-(4-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)phenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
Q27292295

Research Excerpts

Overview

Saterinone was found to be a potent antagonist at vascular alpha 1-adrenoceptors with a pA2-value of 8.46 +/- 0.12.

ExcerptReferenceRelevance
"Saterinone was found to be a potent antagonist at vascular alpha 1-adrenoceptors with a pA2-value of 8.46 +/- 0.12."( Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.
Armah, BI; Hofferber, E; Stenzel, W, 1988
)
1.22

Dosage Studied

ExcerptRelevanceReference
" At the peak of its dose-response curve, saterinone induced an increase in cardiac index (+102%), stroke volume (+97%), and heart rate (+6%), paralleled by a decrease in pulmonary capillary wedge pressure (-46%), right atrial pressure (-51%), pulmonary arterial pressure (systolic -32%, diastolic -45%, mean -38%), systemic blood pressure (systolic -3%, diastolic -13%, mean -9%), systemic vascular resistance (-54%), and pulmonary vascular resistance (-58%)."( Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
Baumann, G; Iven, H; Kieback, AG; Stolzenburg, K, 1998
)
2.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID661114Cytotoxicity against human HuH7 cells after 24 hrs by resazurin reduction assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Latent hit series hidden in high-throughput screening data.
AID661116Antagonist activity at ECMV genomic RNA internal ribosomal entry site in human HuH7 cells after 24 hrs by firefly luciferase reporter gene assay relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Latent hit series hidden in high-throughput screening data.
AID661113Antagonist activity at ECMV genomic RNA internal ribosomal entry site in human HuH7 cells after 24 hrs by firefly luciferase reporter gene assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Latent hit series hidden in high-throughput screening data.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (35.29)18.7374
1990's9 (52.94)18.2507
2000's1 (5.88)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.44 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]